What is the detailed pathophysiology of anaphylaxis and biphasic anaphylactic reactions, and how do glucocorticoids fit into treatment, including why they do not help in acute anaphylactic shock?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Pathophysiology of Anaphylaxis and the Role of Glucocorticoids

Glucocorticoids have no proven role in acute anaphylactic shock because they require 4-6 hours to produce clinical effects—far too slow to reverse the life-threatening cardiovascular and respiratory collapse that defines anaphylaxis. 1

Pathophysiology of Anaphylaxis

Cellular Mechanisms

Anaphylaxis is triggered primarily through IgE-mediated cross-linking of high-affinity IgE receptors (FcεRI) on mast cells and basophils, leading to rapid degranulation 1. However, the pathophysiology extends beyond this classical pathway:

  • Primary effector cells: Mast cells and basophils release preformed mediators (histamine, tryptase) and newly synthesized mediators (cysteinyl leukotrienes, platelet-activating factor, prostaglandins)
  • Additional cellular players: Neutrophils, monocytes, macrophages, and platelets contribute to the inflammatory cascade 1
  • Key mediators: Complement components, IL-6, IL-10, TNF-receptor 1, and platelet-activating factor amplify the systemic response 1

Clinical Manifestations

The massive mediator release causes:

  • Vasodilation and increased vascular permeability → hypotension and distributive shock
  • Bronchial smooth muscle constriction → bronchospasm and respiratory failure
  • Cutaneous manifestations → urticaria, angioedema, flushing
  • Gastrointestinal symptoms → cramping, vomiting, diarrhea

This cascade occurs within minutes, making rapid intervention critical for survival.


Pathophysiology of Biphasic Anaphylaxis

Biphasic anaphylaxis is recurrent anaphylaxis occurring 1-72 hours (up to 78 hours) after complete resolution of the initial episode, with estimates ranging from <1% to 20% of cases 1. The pathophysiology remains incompletely understood, but several mechanisms are proposed:

Proposed Mechanisms

  • Ongoing mediator release: Continued or renewed degranulation of mast cells and basophils
  • Delayed inflammatory cascade: Late-phase allergic response involving cytokine-driven inflammation
  • Incomplete allergen clearance: Persistent antigen exposure triggering recurrent activation
  • Compensatory mechanism failure: Exhaustion of endogenous counter-regulatory responses

Risk Factors for Biphasic Reactions

Severity of initial presentation and requirement for >1 dose of epinephrine are the most consistently identified risk factors 1. Additional predictors include:

  • Severe initial symptoms (hypotension, hypoxia) 2
  • Delayed epinephrine administration (60-190 minutes from symptom onset) 3
  • Unknown or non-food triggers
  • Underlying asthma or cardiovascular disease 1

The majority of biphasic reactions occur >8 hours after the initial event, with many occurring beyond the traditional 4-6 hour observation window 3.


Why Glucocorticoids Don't Work in Acute Anaphylactic Shock

Mechanism of Action (Too Slow)

Glucocorticoids work through genomic mechanisms that are fundamentally incompatible with the time-sensitive nature of anaphylaxis 1:

  1. Glucocorticoids bind to cytoplasmic glucocorticoid receptors
  2. The complex translocates to the nucleus
  3. Gene transcription is modified to inhibit production of new inflammatory mediators
  4. Clinical improvement requires 4-6 hours minimum, regardless of administration route 1

What Glucocorticoids Cannot Do

Unlike epinephrine, glucocorticoids are completely ineffective at reversing the acute manifestations of anaphylaxis because they lack:

  • Vasoconstrictive properties (cannot reverse hypotension)
  • Bronchodilatory effects (cannot reverse bronchospasm)
  • Positive inotropic effects (cannot improve cardiac output)
  • Mast cell stabilization (cannot stop ongoing mediator release)
  • Rapid onset of action (peak effect at 4-6 hours vs. epinephrine's 3-5 minutes) 1

Evidence Against Glucocorticoid Efficacy

Despite widespread use, there is a scarcity of data demonstrating glucocorticoid efficacy in acute anaphylaxis 1. The evidence shows:

  • No proven benefit in preventing biphasic reactions: A 2022 propensity-matched study of 31,570 hospitalized patients found no difference in biphasic reaction rates between those receiving glucocorticoids (10.7%) versus those who did not (10.5%; OR 1.03,95% CI 0.85-1.24) 4
  • No reduction in ED return visits after discharge 1
  • Possible reduction in hospital length of stay, but this does not translate to improved clinical outcomes 1
  • Animal and in vitro data suggest rapid effects (5-30 minutes), but no human data support similar rapid clinical improvement 1

Where Glucocorticoids Fit (If At All)

Current Guideline Position

The 2020 AAAAI/ACAAI practice parameter explicitly states that glucocorticoids should NOT be administered prior to or in place of epinephrine 1. Their role is limited to:

  • Possible adjunctive therapy after epinephrine has been administered
  • Theoretical prevention of protracted or late-phase symptoms (though evidence is lacking)
  • No role in acute shock reversal

Common Pitfall

The most dangerous error is administering glucocorticoids while delaying epinephrine—this directly increases mortality 1. Glucocorticoids continue to be routinely used despite lack of supporting evidence, likely due to:

  • Historical practice patterns
  • Misunderstanding of their mechanism of action
  • Overestimation of their ability to prevent biphasic reactions

Practical Algorithm

For acute anaphylaxis management:

  1. Epinephrine 0.01 mg/kg IM (max 0.5 mg adults, 0.3 mg children) into anterolateral thigh — FIRST and ONLY proven life-saving intervention 1
  2. Position patient supine with legs elevated (if hypotensive)
  3. Administer high-flow oxygen
  4. Establish IV access and give crystalloid bolus (20 mL/kg)
  5. Consider glucocorticoids only AFTER epinephrine, recognizing they will not affect the acute event
  6. Antihistamines may help cutaneous symptoms but do not treat shock or bronchospasm 1

For observation and biphasic risk stratification:

  • Low risk (rapid complete resolution after single epinephrine dose, known food trigger, no cardiovascular/respiratory compromise): Minimum 4-6 hours observation with discharge education
  • High risk (≥2 epinephrine doses, hypotension/hypoxia, delayed initial epinephrine, unknown trigger, comorbid asthma): ≥6-12 hours observation or admission 1, 5

Key Clinical Takeaways

Epinephrine is the ONLY medication proven to reduce anaphylaxis mortality—it must never be delayed 1. Glucocorticoids are ineffective in acute shock because their genomic mechanism requires hours to produce effects, while anaphylaxis kills in minutes. The evidence does not support their use for preventing biphasic reactions 4, and their routine administration represents a persistent gap between practice and evidence 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.